Mesenchymal stem cells and the central nervous system: historical perspectives and future directions - PubMed
a day ago
- #mesenchymal stem cells
- #central nervous system
- #clinical trials
- Mesenchymal stem cells (MSCs) have been studied for about 30 years as a potential therapy for various conditions.
- MSCs show promise in treating central nervous system (CNS) pathologies like Alzheimer's, Parkinson's, ALS, multiple sclerosis, stroke, spinal cord injury, traumatic brain injury, degenerative disc disease, and sepsis/meningitis.
- The therapeutic benefits of MSCs come from their secreted factors, which promote anti-inflammatory and pro-survival pathways while reducing harmful immune responses.
- MSCs are powerful immunomodulatory entities that can enhance endogenous repair mechanisms.
- This review covers the current state of clinical trials for CNS pathologies, focusing on historical progression and upcoming trials.
- The review also discusses the role of the MSC secretome and MSC exosomes in treating CNS pathologies and their increasing use in clinical trials.
- Challenges in clinical translation and implementation of MSC therapies are addressed, along with future directions of the field.